These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 20624322)

  • 21. Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.
    Ulivi P; Chiadini E; Dazzi C; Dubini A; Costantini M; Medri L; Puccetti M; Capelli L; Calistri D; Verlicchi A; Gamboni A; Papi M; Mariotti M; De Luigi N; Scarpi E; Bravaccini S; Turolla GM; Amadori D; Crinò L; Delmonte A
    Clin Lung Cancer; 2016 Sep; 17(5):384-390. PubMed ID: 26712101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinicopathological characteristics of patients with non-small-cell lung cancer who harbor EML4-ALK fusion gene: a meta-analysis.
    Zhao F; Xu M; Lei H; Zhou Z; Wang L; Li P; Zhao J; Hu P
    PLoS One; 2015; 10(2):e0117333. PubMed ID: 25706305
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of five driver gene mutations in patients with treatment-naïve lung adenocarcinoma in Taiwan.
    Hsu KH; Ho CC; Hsia TC; Tseng JS; Su KY; Wu MF; Chiu KL; Yang TY; Chen KC; Ooi H; Wu TC; Chen HJ; Chen HY; Chang CS; Hsu CP; Hsia JY; Chuang CY; Lin CH; Chen JJ; Chen KY; Liao WY; Shih JY; Yu SL; Yu CJ; Yang PC; Chang GC
    PLoS One; 2015; 10(3):e0120852. PubMed ID: 25789627
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer.
    Salido M; Pijuan L; Martínez-Avilés L; Galván AB; Cañadas I; Rovira A; Zanui M; Martínez A; Longarón R; Sole F; Serrano S; Bellosillo B; Wynes MW; Albanell J; Hirsch FR; Arriola E
    J Thorac Oncol; 2011 Jan; 6(1):21-7. PubMed ID: 21107285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
    Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
    Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation.
    Miyanaga A; Shimizu K; Noro R; Seike M; Kitamura K; Kosaihira S; Minegishi Y; Shukuya T; Yoshimura A; Kawamoto M; Tsuchiya S; Hagiwara K; Soda M; Takeuchi K; Yamamoto N; Mano H; Ishikawa Y; Gemma A
    BMC Cancer; 2013 May; 13():262. PubMed ID: 23714228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation between EML4-ALK, EGFR and clinicopathological features based on IASLC/ATS/ERS classification of lung adenocarcinoma.
    Wang H; Zhang W; Wang K; Li X
    Medicine (Baltimore); 2018 Jun; 97(26):e11116. PubMed ID: 29952952
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EML4-ALK rearrangement and its clinical significance in Chinese patients with advanced non-small cell lung cancer.
    Wang Z; Zhang X; Bai H; Zhao J; Zhuo M; An T; Duan J; Yang L; Wu M; Wang S; Wang Y; Wu Y; Wang J
    Oncology; 2012; 83(5):248-56. PubMed ID: 22964709
    [TBL] [Abstract][Full Text] [Related]  

  • 29. KIF5B-RET Fusion gene may coincide oncogenic mutations of EGFR or KRAS gene in lung adenocarcinomas.
    Kim JO; Lee J; Shin JY; Oh JE; Jung CK; Park JK; Sung SW; Bae SJ; Min HJ; Kim D; Park JY; Kang JH
    Diagn Pathol; 2015 Aug; 10():143. PubMed ID: 26268359
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of EML4-ALK fusion genes in a few cancer cells from transbronchial cytological specimens utilizing immediate cytology during bronchoscopy.
    Kanaji N; Bandoh S; Ishii T; Tadokoro A; Watanabe N; Takahama T; Haba R; Imataki O; Dobashi H; Matsunaga T
    Lung Cancer; 2012 Aug; 77(2):293-8. PubMed ID: 22494566
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutations of the EGFR, K-ras, EML4-ALK, and BRAF genes in resected pathological stage I lung adenocarcinoma.
    Ohba T; Toyokawa G; Osoegawa A; Hirai F; Yamaguchi M; Taguchi K; Seto T; Takenoyama M; Ichinose Y; Sugio K
    Surg Today; 2016 Sep; 46(9):1091-8. PubMed ID: 26711128
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of clinical characteristics between patients with ALK-positive and EGFR-positive lung adenocarcinoma.
    Kang HJ; Lim HJ; Park JS; Cho YJ; Yoon HI; Chung JH; Lee JH; Lee CT
    Respir Med; 2014 Feb; 108(2):388-94. PubMed ID: 24361161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing.
    Wallander ML; Geiersbach KB; Tripp SR; Layfield LJ
    Arch Pathol Lab Med; 2012 Jul; 136(7):796-803. PubMed ID: 22742552
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical characteristics of patients with non-small cell lung cancers harboring anaplastic lymphoma kinase rearrangements and primary lung adenocarcinoma harboring epidermal growth factor receptor mutations.
    Xu L; Lei J; Wang QZ; Li J; Wu L
    Genet Mol Res; 2015 Oct; 14(4):12973-83. PubMed ID: 26505450
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
    Cha YJ; Kim HR; Shim HS
    J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinicopathological features of younger (aged ≤ 50 years) lung adenocarcinoma patients harboring the EML4-ALK fusion gene.
    Kometani T; Sugio K; Osoegawa A; Seto T; Ichinose Y
    Thorac Cancer; 2018 May; 9(5):563-570. PubMed ID: 29517858
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical outcomes of thoracic radiotherapy for locally advanced NSCLC with EGFR mutations or EML4-ALK rearrangement.
    Hayashi H; Okamoto I; Kimura H; Sakai K; Nishimura Y; Nishio K; Nakagawa K
    Anticancer Res; 2012 Oct; 32(10):4533-7. PubMed ID: 23060582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy.
    Takeda M; Okamoto I; Sakai K; Kawakami H; Nishio K; Nakagawa K
    Ann Oncol; 2012 Nov; 23(11):2931-2936. PubMed ID: 22771825
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
    Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
    Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.
    Zhang Y; Sun Y; Pan Y; Li C; Shen L; Li Y; Luo X; Ye T; Wang R; Hu H; Li H; Wang L; Pao W; Chen H
    Clin Cancer Res; 2012 Apr; 18(7):1947-53. PubMed ID: 22317764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.